Chromadex Corp expected to post breakeven results a share - Earnings Preview

Niagen Bioscience

29/10/2024 21:06

* Chromadex Corp  CDXC.OQ   CDXC.O  is expected to show a
rise in
quarterly revenue when it reports  results on October 31 for the
period ending January 1 0001
    * The Los Angeles California-based  company is expected to
report
a 21.3% increase in revenue to $23.643 million from $19.5
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Chromadex Corp is for
breakeven results per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chromadex
Corp is
6.35​, above​ its last closing price of $3.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.02       -0.02      0.00      Beat    100
 Jan. 1 0001   -0.02       -0.02      -0.01     Beat    40
 Jan. 1 0001   -0.03       -0.03      0.00      Beat    100​
 Sep. 30 2023  -0.03       -0.03      -0.01     Beat    69.2
 ​​Jan.        -0.04       -0.04      -0.03     Beat    20
 1 0001                                                 
 Mar. 31 2023  -0.05       -0.05      -0.03     Beat    37.5​
 Dec. 31 2022  -0.03       -0.02      -0.02     Met     17.3
 Sep. 30 2022  -0.06       -0.06      -0.04     Beat    35.5
 This summary was machine generated October 29 at 21:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)